Advice
Following an abbreviated submission:
lopinavir/ritonavir (Kaletra®) is accepted for use within NHS Scotland.
Indication under review: in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.
SMC has previously accepted lopinavir/ritonavir for use in children above the age of 2 years.
Download detailed advice101KB (PDF)
Medicine details
- Medicine name:
- lopinavir/ritonavir (Kaletra)
- SMC ID:
- 1302/18
- Indication:
- in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 February 2018